Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-06-22
2000-09-19
Jones, Dwayne C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
424449, 424464, 424468, 424424, A61K 3144
Patent
active
061212768
ABSTRACT:
Psychogenic impotence can be ameliorated without substantial undesirable side effects by administration of apomorphine and an antiemetic agent in an amount sufficient to substantially reduce nausea symptoms associated with the use of apomorphine.
REFERENCES:
patent: 2818855 (1958-01-01), Miller
patent: 3976780 (1976-08-01), Thominet
patent: 4127118 (1978-11-01), Latorre
patent: 4521421 (1985-06-01), Foreman
patent: 4543256 (1985-09-01), Neumeyer
patent: 4569940 (1986-02-01), Watts
patent: 4624965 (1986-11-01), Wenig
patent: 4687773 (1987-08-01), Neumeyer et al.
patent: 4749686 (1988-06-01), Hintze
patent: 4749700 (1988-06-01), Wenig
patent: 4772459 (1988-09-01), Sun et al.
patent: 4801587 (1989-01-01), Voss
patent: 4857553 (1989-08-01), Ward et al.
patent: 5102887 (1992-04-01), Goldberg
patent: 5242391 (1993-09-01), Place et al.
patent: 5270323 (1993-12-01), Milne Jr. et al.
patent: 5310561 (1994-05-01), Jao et al.
patent: 5770606 (1998-06-01), El-Rashidy
Tagliamonte et al., Pharm. Biochem. and Behavior 2;257 (1974).
Laudron et al., Biochem. Pharmacology 28:2161-2165 (1979).
Baldessarini et al., in Gessa et al., eds., vol. 1, Apomorphine and Other Dopaminomimetics, Basic Pharmacology, Raven Press, N.Y. (1981), pp. 219-228.
Lal et al., Neural. Transmission 54:75-84 (1982).
Gower et al., European J. Pharmacology 122:239-244 (1986).
Segraves et al., Arch. Sexual Behav. 16(2):125-137 (1987).
Melis et al., Brain Research 415:98-104 (1987).
Lal, Prog. Neuro-Psychopharm. & Biol. Psych. 12:117-164 (1988).
Pehek et al., Pharm. Biochem. and Behavior 31:201-208 (1988).
Danjou et al. Br. J. Clin. Pharmac. 26:733-739 (1988).
Gancher et al., Ann. Neurol. 26:232-238 (1989).
Danjou et al., Pharmacol. Methods 21:61-69 (1989).
Segraves, Arch. Gen. Psych. 46:275-284 (1989).
Panegyres et al., Med. J. Australia 155:371-374 (1991).
Lal et al., J. Psych. Neurosci. 16(5):262-266 (1991).
Heaton et al., J. Urology 145:1099-1102 (1991).
Montastruc et al., Clin. Neuropharmacology 14(5):432-437 (1991).
Durif et al., Eur. J. Clin. Pharmacology 41:493-494 (1991).
Gancher et al., Movement Disorders 6(3):212-216 (1991).
Essink et al., J. Chromatography 570:419-424 (1991).
Segraves et al., J. Urology 145:1174-1175 (1991).
Durif et al., Clinical Neuropharmacology 16(2):157-166 (1993).
Segraves, R.T., Dopamine agonists and their effect on the human penile erectile response, pp. 225-229 in Bancroft, J., editor, The Pharmacology of Sexual Function and Dysfunction, Excerpta Medica, Amsterdam (1995).
El-Rashidy Ragab
Ronsen Bruce
Delacroix-Muirheid C.
Jones Dwayne C.
Pentech Pharmaceuticals, Inc.
LandOfFree
Apomorphine-containing dosage forms for ameliorating male erecti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apomorphine-containing dosage forms for ameliorating male erecti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apomorphine-containing dosage forms for ameliorating male erecti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073519